Researchers from Rutgers University, St. Jude Children's Research Hospital, Medicines for Malaria Venture, University of South Florida, UCSF, Monash University, Australian National University, Griffith University, Columbia University, University of British Columbia, Eisai, SRI, GSK, and Syngene collaborated on hit compound identification, SAR studies, ADMET, in vitro, and in vivo evaluation, and preparative chemistry to produce SJ733, a new antimalarial now in clinical trials in humans. For combatting malaria and other diseases of the developing world, this multilateral mode of drug development, with significant contributions from academia, now takes precedence over the more traditional big pharma do-it-all-in-house paradigm.

Massively collaborative drug development: A new antimalarial emerges from academia

254th National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.